Ivenix, Inc.

Ivenix, Inc. specializes in advanced infusion systems that enhance the safety and accuracy of intravenous medication delivery, primarily targeting critical care environments such as hospitals. Founded in 2007 and headquartered in North Andover, US, Ivenix, Inc. focuses on providing innovative infusion technology.

The company has completed 12 deals and recently raised USD 10. 00 mn in funding from 6 Dimensions Capital and F-Prime Capital. Ivenix was involved in a significant acquisition where Fresenius Kabi AG agreed to acquire a majority stake for USD 240 mn, a transaction expected to close by mid-2022, aimed at expanding its biopharmaceutical market presence. Ivenix is primarily recognized for its advanced infusion system, designed to enhance the accuracy and safety of intravenous medication administration.

The Ivenix Infusion System offers an overall accuracy of +/- 5% under various conditions, accommodating flow rates from 0. 5 to 1000 mL/hr and operating effectively in ambient temperatures ranging from 5°C to 35°C. This innovative system caters to healthcare professionals by enabling efficient management of medication delivery, specifically targeting critical care environments such as hospitals and surgical centers. The device is engineered to handle various fluid viscosities, including solutions up to 70% dextrose, and is suitable for extended use up to 96 hours.

Marketed primarily in the United States, the Ivenix Infusion System serves a diverse clientele, including hospitals, outpatient clinics, and healthcare providers that prioritize precision in patient care. Ivenix’s revenue model is built around the sale and distribution of its infusion system and associated services. The company engages in B2B transactions, predominantly establishing partnerships with healthcare institutions that require state-of-the-art infusion technology. These transactions typically involve direct sales agreements, with clients purchasing the infusion systems and possibly entering into service contracts for maintenance and support.

The flagship product, the Ivenix Infusion System, is expected to drive significant revenue through these structured sales, ensuring reliable performance and safety standards in medication delivery. Pricing structures encompass upfront costs for the infusion system, with potential recurring fees for servicing and maintenance, thereby fostering long-term relationships with healthcare providers. Ivenix plans to strengthen its market position through the launch of new and enhanced infusion products designed for critical care applications. Funding raised will support these product developments and facilitate expansion into new geographical markets, particularly focusing on increasing its footprint in Europe and Asia by 2024.

The acquisition by Fresenius Kabi AG aims to accelerate Ivenix’s growth trajectory in the biopharmaceuticals sector, enhancing its resources and capabilities in delivering innovative healthcare solutions.